Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy

Xiao-Jing Pang 1, Xiu-Juan Liu 1, Yuan Liu 1, Wen-Bo Liu 1, Yin-Ru Li 2, Guang-Xi Yu 2, Xin-Yi Tian 2, Yan-Bing Zhang 1, Jian Song 1,2,* , Cheng-Yun Jin 1,2,* and Sai-Yang Zhang 1,2,3,4,*

Abstract: FAK is a nonreceptor intracellular tyrosine kinase which plays an important biological function. Many studies have found that FAK is overexpressed in many human cancer cell lines, which promotes tumor cell growth by controlling cell adhesion, migration, proliferation, and survival. Therefore, targeting FAK is considered to be a promising cancer therapy with small molecules. Many FAK inhibitors have been reported as anticancer agents with various mechanisms. Currently, six FAK inhibitors, including GSK-2256098 (Phase I), VS-6063 (Phase II), CEP-37440 (Phase I), VS-6062 (Phase I), VS-4718 (Phase I), and BI-853520 (Phase I) are undergoing clinical trials in different phases. Up to now, there have been many novel FAK inhibitors with anticancer activity reported by different research groups. In addition, FAK degraders have been successfully developed through “proteolysis targeting chimera” (PROTAC) technology, opening up a new way for FAK-targeted therapy. In this paper, the structure and biological function of FAK are reviewed, and we summarize the design, chemical types, and activity of FAK inhibitors according to the development of FAK drugs, which provided the reference for the discovery of new anticancer agents.

Keywords: focal adhesion kinase; anticancer activity; diaminopyrimidines; triazine; PROTAC

1. Introduction

Receptor tyrosine kinases (RTK) and non-receptor tyrosine kinases play vital roles in extracellular signals and process of cancer cell migration, proliferation, and survival, which usually are overexpressed in many human cancer cells [1,2]. Therefore, targeting RTKs and non-receptor tyrosine kinases has been considered to be a promising therapy for the treatment of human cancers [3].

FAK is one of cytoplasmic non-receptor protein tyrosine kinase, which is a member of the focal adhesion complex family [4,5]. FAK is a 125 kDa protein that is recruited in the early stages of cell adhesion and phosphorylated to mediate the formation of local adhesion [6–9]. FAK gene exists on chromosome 8q24 and encodes 1052 amino acid residues and its protein structure consists of three parts: N-terminal region, kinase region, and C-terminal region [9].

FAK was first discovered in 1992, which is related to integrin signal transduction [4]. FAK is considered to be a key regulator of growth factor receptor and integrin-mediated signaling, which controls the basic processes of human normal or cancer cells through its kinase activity and scaffold function [10,11]. FAK overexpression is detected in various tumor types, including prostate cancer, breast cancer, lung cancer, ovarian cancer, and...
neck cancer, and FAK is also associated with the poor prognosis of cancer patients [12,13]. Besides, it is related to unregulated proteins in cancer, providing a perfect environment for FAK-specific treatment [14]. FAK regulates tumorigenic and metastatic potential through a highly coordinated signal network, thereby promoting the occurrence of malignant tumors. These signal networks coordinate a series of cellular processes, such as cell proliferation, survival, invasion, migration, angiogenesis, and the regulation of cancer stem cell activity [5,15,16]. Different FAK antisense oligonucleotides [17], dominant-negative FAK C-terminal domain, FAK-CD or FRNK or FAK-siRNA [18,19] can lead to decreased cell survival, growth inhibition, or apoptosis. In recent years, FAK has been considered as a new potential tumor-treatment target [20].

So far, some FAK inhibitors have been identified and proved to be effective inhibitors that inhibit the tumor growth and metastasis in several preclinical and clinical models [21–24]. TAE-226 is a typical FAK inhibitor (IC₅₀ = 5.5 nM), which has strong antiproliferative and anticancer potency against several types of cancers in vitro and in vivo [21]. GSK2256098 is a highly potent, ATP-competitive, and reversible FAK inhibitor [25], which is currently underway in clinical trials as a monotherapy or in combination with other drugs for patients with brain tumors or other cancers [26]. VS-6063 is a highly effective second-generation FAK inhibitor. Phase II clinical trials of VS-6063 in patients with KRAS mutant non-small cell lung cancer have been completed [27]. VS-6062 has now completed the first phase of research. VS-6062 not only exhibits significant antiproliferation potency of cancer cells but also plays a new role in changing tumor microenvironment [28]. VS-4718 significantly affects cell viability by inhibiting FAK activity and locking Y397 phosphorylation [23,24]. Another novel FAK inhibitor, CEP-37440, is currently in clinical trials for the treatment of cancers [22] (Table 1). The proteolytic targeting chimera (PROTAC) that can induce FAK degradation by using FAK kinase inhibitors as a “warhead” also has been developed [29]. A large number of studies have provided convincing evidence that FAK inhibitors could be used as chemical-targeted drugs to induce growth inhibition and apoptosis of cancer cells [30–32]. This article briefly introduces the structure and biological functions of FAK. Aiming at the development of FAK drugs, it focuses on the design, chemical types, and activities of FAK drugs to provide references for the development of new antitumor drugs.

Table 1. All reported FAK inhibitors in clinical trials.

| Inhibitor     | Structure | Target (IC₅₀) | Company       | Clinical Trial | Status       | Identifier       |
|---------------|-----------|---------------|---------------|----------------|--------------|------------------|
| GSK-2256098   | ![Structure](image1.png) | FAK IC₅₀ = 0.4 nM | Glaxo Smith Kline | phase I        | completed     | NCT01138033, NCT00996671, NCT02551653 |
| VS-6063       | ![Structure](image2.png) | FAK IC₅₀ = 0.6 nM | Verastem      | phase II       | completed     | NCT01943292, NCT00780703, NCT01951690 |
| VS-6062       | ![Structure](image3.png) | FAK IC₅₀ = 1.5 nM | Verastem      | phase I        | completed     | NCT00666926      |
| VS-4718       | ![Structure](image4.png) | FAK IC₅₀ = 1.5 nM | Verastem      | phase I        | terminated    | NCT01849744, NCT02215629 |
Table 1. Cont.

| Inhibitor       | Structure | Target (IC₅₀) | Company               | Clinical Trial | Status     | Identifier       |
|-----------------|-----------|--------------|-----------------------|----------------|------------|------------------|
| CEP-37440       |           | FAK IC₅₀ = 2 nM ALK IC₅₀ = 3.1 nM | Teva Branded         | phase I        | completed   | NCT01922752      |
| BI-853520 (IN-10018) | Unknown FAK | Boehringer Ingelheim | phase I               | completed      | completed   | NCT01335269 NCT01905111 |

2. FAK Structure and Function

The FAK protein molecule can be roughly divided into N-terminal FERM region, middle kinase region, C-terminal focal adhesion target (FAT), and proline-rich regions (PRR1, PRR2, and PRR3). FAK has 6 tyrosine sites that can be phosphorylated: Y397, Y407, Y576, Y577, Y861, and Y925, all of them are the key parts in FAK’s signal transduction. Y397 and Y407 sites are located at the N-terminus, Y576 and Y577 are located in the activation loop of the kinase region, and Y861 and Y925 are located at the C-terminus. Y397 is an autophosphorylation site of FAK, which provides a high-affinity-binding site for Src family proteins and plays a vital role in downstream signaling pathways [16].

There are binding sites for a variety of proteins at the N-terminus, such as signal transduction proteins, cytoskeleton proteins, and integrin β subunits [33]. The N-terminal FERM domain is composed of three closely related subdomains F1, F2, and F3, forming a three-leaf clover-like structure [34] (Figure 1). Among of them, F1 and F2 subdomains can interact with p53 and hinder the apoptosis of tumor cells; the F2 subdomain can regulate kinase-independent activities and mediate cell survival; the F3 subdomain can interact with Mdm-2 to enhance ubiquitination of p53 [33]. The kinase domain of FAK also called the catalytic domain, has a highly conserved amino acid sequence that can phosphorylate corresponding amino acid residues in proteins such as PI3K, growth factor receptor-binding protein 2 (GRB2), Src, and Cas. The focal adhesion targeting region at the C-terminus could interact with focal adhesion proteins, including paxillin [35], Talin [36], and Vinculin [37]. FAT can also bind to the F2 leaf in the FERM domain, leading to the dimerization of FAK, which is of great significance to the activation and nuclear localization of FAK [38]. PRR1 is located between the FERM region and the kinase region and has a binding site to the SH3 domain, which can bind to proteins such as Src. PRR2 and PRR3 near the C-terminus can mediate the interaction between FAK and protein molecules containing SH3 domains.

Figure 1. Schematic diagram of the molecular structure of FAK protein.

FAK shows kinase-dependent enzyme function and a kinase-independent scaffold function, which play important roles in regulating the survival, proliferation, migration, and angiogenesis of cancer cells. FAK is overexpressed in many human cancers, including
glioma, breast, colon, prostate, and other cancers [10,16,39]. Inhibition of FAK has been shown to inhibit tumor progression and metastasis.

3. The Discovery of FAK Inhibitors and Their Therapeutic Significance

Because of its important roles in human cancer cells, targeting FAK inhibitors is emerging as a promising target for cancer therapy with small molecules. Currently, six FAK inhibitors are undergoing clinical and many FAK inhibitors have been reported with strong inhibitory activity of FAK and significant antiproliferation potency against cancer cells (Table 1). In this section, we summarized the progress for the development of FAK inhibitors.

3.1. FAK Inhibitors in Clinical Trials

**GSK2256098** is a highly effective and selective FAK inhibitor (IC$_{50}$ = 0.4 nM). GSK2256098 significantly inhibited FAK-Y397 phosphorylation in A549, OVCAR8, and U87MG cells (IC$_{50}$ = 12, 15, and 8.5 nM, respectively). **GSK2256098** inhibited FAK Y397 phosphorylation and then suppressed FAK-related Akt/ERK activation, which led to the decrease of cell viability, anchorage-independent growth, and motility in a dose-dependent manner in pancreatic ductal adenocarcinoma cells [40]. The results of the phase I trial of **GSK2256098** in sixty-two patients with advanced solid tumors suggested **GSK2256098** had an acceptable safety profile and showed clinical activity in patients with mesothelioma. A phase Ib trial study indicated that **GSK2256098** combined MEK inhibitor trametinib in the treatment of patients with advanced solid tumors could increase the exposure of trametinib and has an acceptable safety profile [26].

**VS-6063** is another FAK and Pyk2 dual inhibitor with more effective activity against FAK and Pyk2 than that of **VS-6062**. **VS-6063** inhibited FAK-Y397 phosphorylation in a time and dose-dependent manner in ovarian cancer cells. The combination of **VS-6063** with paclitaxel could significantly exhibit the antiproliferation effects and increased apoptosis in ovarian cancer cells [24]. Notably, **VS-6063** could overcome YB-1-mediated paclitaxel resistance by an AKT-dependent pathway. **VS-6063** showed an acceptable safety profile in forty-six patients with advanced solid tumors according to the results of phase I trial [27]. The phase II trial, multicenter cohorts, open-label, single-arm study of **VS-6063** treatment in heavily patients with KRAS mutant NSCLC indicated **VS-6063** monotherapy demonstrated modest clinical activity [41].

**VS-6062** is an ATP-competitive FAK and Pyk2 dual inhibitor, which displayed significant inhibitory potency of FAK and Pyk2 (IC$_{50}$ = 1.5 and 14 nM, respectively) [42]. **VS-6062** potently blocked FAK-Y397 phosphorylation in a dose-dependent manner in Ewing sarcoma cell lines which resulted in the downregulation of its downstream targets AKT/mTOR and CAS activity. **VS-6062** could suppress the growth and colony formation, and induced apoptosis in Ewing sarcoma cell lines [43]. The combined treatment of **VS-6062** with sunitinib could potently inhibit angiogenesis and tumor proliferation on liver solid tumor models [44]. In addition, **VS-6062** has been reported to be an effective antimitotic and antiangiogenic agent, which could potently suppress EOC and endothelial cell migration and endothelial cell tube formation in vitro [45]. The results of phase I trial of **VS-6062** in ninety-nine patients with advanced solid tumors indicated that **VS-6062** showed an acceptable safety profile and displayed time- and dose-dependent nonlinear PK [46].

**VS-4718** is a highly effective and selective FAK inhibitor (IC$_{50}$ = 1.5 nM) [47]. **VS-4718** displayed potent inhibition activity with IC$_{50}$ values ranging from 0.25 µM to 3.53 µM in vitro in a pediatric preclinical testing program (PPTP) and exhibited excellent tolerance in PPTP preclinical xenografts in vivo [48]. In addition, it has been reported that **VS-4718** could antagonize the multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells through competitively interacting with ABCB1 and ABCG2 and affecting the activity of ABCB1 and ABCG2, which indicated that **VS-4718** combines with other anticancer drugs may antagonize the multidrug resistance [49–52]. The phase 1 clinical trial of **VS-4718**
combined with paclitaxel and gemcitabine for the treatment of advanced pancreatic cancer has been completed [53].

**CEP-37440** is a potent FAK and ALK dual inhibitor with strong and selective inhibition activity of FAK and ALK (IC$_{50}$ = 2.0 and 3.1 nM, respectively). **CEP-37440** effectively suppressed the proliferation of Sup-M2 and Karpas-299 cells (NPM-ALK+ ALCL cell lines) with IC$_{50}$ values 84 and 131 nM, respectively. **CEP-37440** displayed favorable in vitro ADME properties and acceptable oral bioavailability in CD-1 mice, Sprague–Dawley rats, and cynomolgus monkeys. In addition, **CEP-37440** is effective in preclinical models of FC-IBC02, SUM190, and KPL4 with GC$_{50}$ values of 91, 900, and 890 nM, respectively [22,54]. **CEP37440** is currently undergoing a human clinical phase I trial.

**CEP-37440** was discovered by the optimization of lead compound 1 which is an ALK inhibitor containing a diaminopyrimidine core motif [55–57] (Figure 2A). When morpholine was switched to N-methyl piperazine (compound 2), the stability of compound 2 in rat liver microsomes was significantly improved without eroding the potency or selectivity. Based on these promising results of compound 2, the strategy is to further increase the inhibitory potency of ALK, maintaining the activity of auxiliary FAK, and improve the metabolic stability of human liver microsomes. Changing the substituent of N-methyl on the piperazine to a hydroxyethyl substituent (compound 3) showed more potent inhibitory activity against enzymes and cells. Based on compound 3, changing the bicycloheptene system to 2-(N-methylmethanesulfonamide) benzene ring gave compound 4, which exhibited similar ALK enzyme and cells inhibitory potency. When the 2-N, N-dimethylsulfonamide substituent was replaced with N-methylamide substituent (**CEP-37440**), it displayed acceptable oral bioavailability (47%) and demonstrated acceptable in vitro liver microsome stability across species (rat and human t$_{1/2} > 40$ min) and also exhibited great inhibitory potency of ALK and FAK. The molecular docking results also explained that compound **CEP-37440** exhibited great dual ALK/FAK potency (Figure 2B) [22,58].

3.2. Pyrimidine FAK Inhibitors

In 2006, Novartis researchers first reported an ATP-competitive FAK inhibitor named as **TAE-226** (Figure 3A). **TAE-226** is a highly effective and orally active FAK and Pyk2 dual-target inhibitor [59]. **TAE-226** exhibited a wide spectrum of antiproliferation activity against various human cancer cells with a mean GI$_{50}$ value of 0.76 µM [60]. **TAE-226** potently inhibited FAK-Y397 autophosphorylation and blocked FAK-mediated downstream signaling pathways [61]. **TAE-226** showed a strong antitumor effect through suppressing migration and metastasis, and induced increased apoptosis in a variety of cancer cells, such as glioma, breast, ovarian, and neuroblastoma cells [62]. The crystal structure of **TAE-226** complexed with the kinase domain of FAK has been determined (Figure 3B), which clearly demonstrates the interaction of **TAE-226** with FAK [63]. However, in consideration of its serious side effects on sugar metabolism, **TAE-226** never entered clinical trial but is usually compared with other newly developed FAK inhibitors as a positive drug [64].

**PF-573228** (Figure 4) is the first selective and potent ATP-competitive FAK inhibitor developed by Pfizer [65], which potently suppressed the FAK activity with an IC$_{50}$ of 4 nM and the phosphorylation of FAK on Tyr397 with IC$_{50}$ values of 30–100 nM in F-G, SKOV-3 and PC3 cells. **PF-573228** inhibited the chemotactic and haptotactic migration, resulting in concomitant with the inhibition of focal adhesion turnover in REF52 cells. **PF-573228** could not inhibit the cell growth or induce cell apoptosis in REF52 and PC3 cells [66]. Based on the structural modifications of **PF-573228**, another two analogs **VS-6062** and **VS-6063** developed by Pfizer have been used in clinical trials.
Figure 2. (A) The discovery of compound CEP-37440. (B) Glide docking of CEP37440 (gray) and compound 1 (yellow): left panel, ALK (PDB code 3LZT); right panel, FAK (PDB code 3BZ3).

2-Anilino-4-(benzimidazol-2-yl) pyrimidine 9 is a multi-kinase inhibitor with inhibitory potency of FAK, PLK1, Aurora B, and VEGF-R2 with IC\textsubscript{50} values of 3.4, 1.2, 6, and 7.2 µM, respectively (Figure 5). Compound 9 also exhibited potent inhibition growth of SW-620, MDA-MB-435, OVCAR-3, CAKI-1, and MCF-7 cells at micromolar concentrations (IC\textsubscript{50} values = 0.62, 0.19, 0.93, 0.86 and 0.47 µM, respectively) [67].
Farand’s group reported novel macrocycle diphenylpyrimidine derivatives as FAK inhibitors based on the lead compound VS-6062 in 2016 (Figure 6). The representative compound 10 showed strong antagonism against FAK and Pyk2 with IC<sub>50</sub> values of 4.34 nM and 0.84 nM, respectively [68]. Among these compounds, compound 10 showed the best metabolic stability in the analysis of human microsomes.

Sulfonamide functional groups exist in many active compounds and exhibit antibacterial, anticancer, and antiviral activities [69–71]. Previous studies have shown that the introduction of functional sulfonamides into the C-2 aniline portion of the pyrimidine core could increase the inhibitory potency of Bruton’s tyrosine kinase (BTK), which is a successful and effective drug target for the treatment of B lymphocytic leukemia [72]. Therefore, Ma’s group synthesized novel diphenylpyrimidine derivatives (Figure 7) through the introduction of sulfonamide functional groups based on the famous FAK inhibitor TAE-226 to improve the anti-FAK activity and biological activity in 2017 [73].
Figure 6. Macrocyclic double-target inhibitors of FAK and Pyk2 were obtained by cyclization.

Figure 7. Discovery of diphenylpyrimidine derivatives with sulfonamide functional groups as FAK inhibitors.
These new compounds showed moderate anti-FAK enzyme activity compared to TAE-226 ($IC_{50} = 5.5$ nM). The most active compound 18 effectively inhibited FAK activity with an $IC_{50}$ value of 86.7 nM. It is worth noting that compound 18 exhibited significantly inhibitory potency against pancreatic cancer cells ASPC-1 and PANC-1 with $IC_{50}$ values of 3.92 and 0.53 µM, respectively, which were lower than that of TAE-226 ($IC_{50} = 6.73$ and >20 µM, respectively). Compound 18 also promoted the apoptosis of pancreatic cancer cells in a dose-dependent manner. Molecular docking results showed compound 18 bonded to the FAK enzyme tightly and the interaction with the FAK enzyme was similarly to TAE-226, which might explain compound 18 shows potent anti-FAK activity (Figure 8B). These results provide a theoretical basis for further optimizing the structure of novel sulfonamide compounds as FAK inhibitors.

In general, most of the potent FAK inhibitors have pyrimidine templates and N-methyl formamide substituted anilines, which are necessary to interact with amino acids Cys502, Asp564, and Leu567 of FAK protein to interfere with FAK activity [74–76]. Phosphorylated functional groups are very effective in improving the water solubility and biological activity of anticancer agents [77–79]. Ma’s group discovered that the introduction of phosphoryl groups on the C-2 aniline side chain of the pyrimidine core could improve its inhibitory activity of BTK and antiproliferation activity against B-cell leukemia cells [80–83]. In 2017, they designed and synthesized a series of novel diphenylpyrimidine analogues containing phosphamides as FAK inhibitors [84] (Figure 9).

![Figure 8. (A) Chemical structure of compound 18. (B) Predicted binding pose of compound 18 in FAK enzyme (PDB code: 2JKK).](image)

![Figure 9. The fragment-based drug design strategy of compound 24.](image)
Most of the phosphamide-containing diphenylpyrimidine analogs showed good activity against FAK, which were equivalent or showed stronger inhibition than that of TAE-226 (IC\textsubscript{50} = 5.5 nM). Compound 24 exhibited stronger anti-FAK activity (IC\textsubscript{50} = 4.65 nM), which was stronger than that of TAE-226. Importantly, compound 24 also exhibited a potent capacity to decrease the growth of AsPC-1 and BxPC-3 cells with IC\textsubscript{50} values 1.66 and 0.57 \textmu M, respectively, which was lower than that of TAE-226 (IC\textsubscript{50} = 6.73 and 1.03 \textmu M, respectively). Interestingly, compound 24 was not active against normal HPDE6-C7 cells (IC\textsubscript{50} > 20 \textmu M). In addition, compound 24 induced the apoptosis of AsPC-1 cells in dose and time-dependent manners and arrested AsPC-1 cells in a G2/M phase. The docking results indicated that compound 24 could well dock into the ATP-binding pocket of the FAK enzyme which is similar to lead compound TAE-226 (Figure 10). It is worth noting that compound 24 forms three strong hydrogen bonds, which are produced by the N-1 atom in the pyrimidine core with amino acid Cys502, the carbonyl group in N-methylbenzamide with the amino acid Asp564, and the nitrogen atom in N-methylbenzamide with Arg505 and Gly506 through a water molecule. Notably, the morpholine substituent and the ethoxyl group of compound 24 could form strong contacts with the amino acid Gly505 and Glu506 through the polar-induced forces.

Small molecule inhibitors targeting FAK are usually designed to bind residues that surround the ATP-binding pocket of FAK, including TAE-226, PF562271, and CEP-37440, etc. These inhibitors are composed of pyrimidine core and N-methylbenzamide functional group. The co-crystal structure of the complex of FAK and TAE226 shows that the hydrophilic functional group on its C-2-aniline side chain is beneficial to strengthen the contact with the amino acids Gln438 and Gly505 in the FAK protein-binding pocket [63,85]. In fact, efforts in the structural modification of pyrimidine scaffolds have found several FAK inhibitors that are more effective than TAE226, such as compounds 18 and 24 (Figures 8 and 10), which indicated that structural modifications such as the introduction of sulfonate or phosphonate groups at C-2-aniline side chain are beneficial to increase the binding affinity with FAK. Therefore, Ma’s group introduced the N-morpholine carbamide functional group on the aniline side chain at the C-2 position of the pyrimidine core to design novel carboxamide-diphenylpyrimidines with strong hydrogen bond affinity to FAK in 2019 (Figure 11) [86].
Figure 11. Compound 25 was obtained by structural modification.

Most carboxamide-diphenylpyrimidines displayed high inhibitory potency of FAK activity with IC_{50} values ranging from 2.58 to 75.8 nM. Among them, compound 25 exhibited equal anti-FAK activity (IC_{50} = 5.17 nM) to the lead compound TAE-226 (IC_{50} = 5.5 nM). Significantly, compound 25 also displayed potent antiproliferation potency against AsPC-1, BxPC-3, and MCF-7/ADR cells (IC_{50} = 0.105, 0.09 and 0.59 µM, respectively), which were much lower than that of the lead compound TAE-226 (IC_{50} = 6.73 µM, >10 and >10 µM, respectively). Compound 25 potently inhibited FAK phosphorylation in a dose-dependent manner and completely inhibited it at a concentration of 50 nM for 72 h in AsPC-1 cells, while the lead compound TAE-226 completely inhibited FAK phosphorylation at a concentration of 100 nM. In addition, compound 25 also exhibited great antitumor efficacy in an AsPC-1 cancer xenograft mouse model. The results of molecule docking clearly suggested that compound 25 could tightly and similarly bind to the active site of FAK as the compound TAE-226 (Figure 12). Notably, compound 25 formed a strong hydrogen bond between the oxygen atom of the amide group and amino acid Asp564, which is similar to that of TAE-226 but also formed a new strong hydrogen bond through the carbonyl group with amino acid Gln438.

Recently, the discovery of irreversible covalent inhibitors targeting kinases has attracted great interest [87,88], which shows unique advantages, for example, irreversible covalent inhibitors could prolong the target retention time and obtain long-lasting inhibition without continuous administration, as well as reduce the development of drug-resistant mutations and better avoid resistance [89]. The crystal structure of FAK protein with TAE-226 clearly indicates that Cys427 on the glycine-rich loop of FAK locates close to the ATP-binding site. Therefore, this cysteine residue could be used as the nucleophilic group for the design of covalent FAK inhibitors. Chen’s group successfully discovered novel FAK inhibitors by the introduction of an acrylamide moiety to the pyrimidine scaffold of TAE-226 in 2018 (Figure 13) [90]. These compounds with appropriate linkers could ensure that
acrylamide group can be in proximity to Cys427 of FAK protein and the 2,4-diphenylamine pyrimidine as a core scaffold to maintain the binding affinity with the FAK protein.

Figure 12. (A) Chemical structure of compound 25. (B) Predicted binding models of TAE-226 (red) and compound 25 (blue) in FAK enzyme (PDB code: 2JKK).

These compounds exhibited superior inhibitory potency against FAK with IC\textsubscript{50} values ranging from 0.6 to 4.7 nM, which were lower than that of the lead compound TAE-226. Compound 30 bearing a squarate group displayed better inhibitory activity than compounds 32 and 33. Compound 30 also exhibited excellent antiproliferation activity of squamous cell carcinoma (SCC) cells with a similar ED\textsubscript{50} (IC\textsubscript{50} = 1.73 \(\mu\)M) to that of VS-4718 (IC\textsubscript{50} = 1.49 \(\mu\)M). Besides, compound 30 significantly blocked Tyr397 phosphorylation and the autophosphorylation of FAK at low concentrations in SCC cells, which was comparable to VS-4718. The cocrystal structure of the FAK kinase domain with compound 30 shows that 30 makes a covalent bond with Cys 427 of the FAK kinase domain by means of its carbamate linker (Figure 14).
Molecular hybridization strategy is a common method of designing new drugs based on the combination of different biologically active parts to produce novel hybrids with higher affinity and effectiveness [91]. Before 2019, there was no report on 2,4-diarylaminopyrimidine dithiocarbamate hybrid compounds. The combination of 2,4-diarylaminopyrimidine and dithiocarbamate into one compound exhibited the potential to enhance its anti-FAK activity and antiproliferative effects [92,93]. Yin’s group designed a class of 2,4-diarylaminopyrimidines as novel FAK inhibitors by incorporating the dithiocarbamate moiety in 2019 (Figure 15) [94]. It is found that the different structural units of R have a great influence on FAK and cell inhibitory activity. Among of these compounds, compound 34 exhibited the highest inhibitory potency of FAK (inhibition rate = 73% at 1 µM). Compound 34 was selected as a new starting point for further optimization and retained the N,N-dimethylaminoethyl group. However, the introduction of a strong electron-withdrawing group, such as trifluoromethyl (compound 35), could significantly increase the FAK-inhibitory activity. Compound 35 exhibited more potent inhibitory activity against FAK (IC50 = 0.07 nM) compared to TAE-226 and excellent antiproliferative effects against HCT-116, PC-3, U87-MG, and MCF-7 cell lines with IC50 values of 1, 30, 60, and 20 nM, respectively, which were significantly lower than that of the lead compound TAE-226 (IC50 = 290, 1680, 1660, and 560 nM, respectively). Moreover, compound 35 significantly induced apoptosis by arresting cell cycle in G2/M phase in both MCF-7 and HCT-116 cell lines.

In recent years, with the development of polypharmacology and a deep understanding of tumor pathogenesis, multi-targeting antitumor agents have been considered as an important strategy to overcome drug resistance and improve therapeutic effects. Based on a fragment-based drug design strategy, Chen’s group discovered a new class of diphenylpyrimidine derivatives as potent FAK and EGFRT790M dual inhibitors in 2020 (Figure 16) [95]. Epidermal growth factor receptor (EGFR) tyrosine kinase has been proved to be a valuable clinical target for anticancer therapy, especially for NSCLC [96,97]. However, the T790M mutation (threonine to methionine) within the ATP site of the EGFR frequently occurs in NSCLC patients (about 60%), and these patients develop resistance to drugs that target EGFR, which leads to the failure of EGFR-targeted therapy [98,99]. In addition, novel EGFRT790M inhibitors such as CO-1686 (Phase III) and AZD-9291 consist of the core scaffold of pyrimidine. Therefore, they designed and synthesized the first novel dual FAK and EGFRT790M inhibitors using a fragment-based drug design strategy based on the lead compound TAE-226 and Rociletinib. Fortunately, most of them exhibited great inhibitory potency of FAK and EGFR T790M.
Figure 15. The design strategy of 2,4-diarylaminopyrimidine derivatives by incorporating the dithiocarbamate moiety.

Among these compounds, compound 41 not only exhibited high inhibitory activity of FAK kinase ($IC_{50} = 1.03$ nM) and EGFR $^{T790M}$ ($IC_{50} = 3.89$ nM) but also displayed excel-
lent antiproliferative activity against AsPC-1, BxPC-3, Panc-1 three FAK-overexpressing pancreatic cancer cells (IC$_{50}$ = 0.909, 0.761, 1.218 µM, respectively) and two drug-resistant cancer cell lines MCF-7/ADR and H1975 cells (IC$_{50}$ = 0.909, 0.761, 1.218 µM, respectively), which were significantly lower than that of the lead compound TAE-226. In addition, compound 41 also showed the efficiency in the in vivo assessment conducted in a FAK-driven human AsPC-1 cell xenograft mouse model.

Chen’s group reported another new class of irreversible covalent FAK inhibitors based on compound 30 in 2020 (Figure 17) [100]. Among them, compound 45 exhibited more effective and selective inhibition potency of FAK with an IC$_{50}$ value of 0.6 nM than that of TAE-226. Compound 45 potently suppressed the proliferative activity of three human glioblastoma cell lines U-87 MG, A172, and U251 with IC$_{50}$ values of 7.2, 0.89, and 1.2 µM, respectively, which were lower than that of the lead compound TAE-226 (IC$_{50}$ = 2.9, 8.3 and 6.3 µM, respectively). Compound 45 could significantly suppress the autophosphorylation of FAK in U-87 MG cells at low concentrations and block the phosphorylation of FAK-Tyr397 in a dose-dependent manner. In addition, compound 45 also significantly reduced the rate of cell migration and blocked U-87 cells in the G2/M phase.

![Figure 17. Discovery of reversible valence FAK inhibitors. Compound 30 and compound 45 came from the same research group.](image-url)
Positron emission tomography (PET) is an advanced clinical imaging technology in the field of nuclear medicine. In recent years, many groups discovered novel small molecule PET-imaging agents through 18F labeling strategies based on anticancer agents with dual biological properties. Zhang’s group first reported F-18-labelled 2,4-diaminopyrimidines as FAK inhibitors and tumor-imaging agents (Figure 18) [101]. These compounds displayed superior inhibition potency against FAK with IC50 values ranging from 5.0 nM to 205.1 nM. Interestingly, compounds 52 and 53 which were labeled by 18F exhibited respective IC50 values of 5.0 nM and 21.6 nM. In addition, compound 52 exhibited promising biodistribution data in sarcoma S180-bearing mice, with tumor/blood, tumor/muscle, and tumor/bone ratios of 1.17, 2.99, and 2.19, respectively.

Zhang’s group reported novel 2,4-diaminopyrimidine derivatives FAK as tumor radiotracers in 2021 (Figure 19) [102]. Among them, compounds 54, 55, and 58 exhibited potently inhibitory activity against FAK with IC50 values of 3.0, 0.6, and 3.2 nM, respectively. Replacement of the chlorine atom in the pyrimidine ring with other groups assisted in penetrating the protein pocket and maintaining a low IC50 level. Furthermore, compound 58 with a FAK titer was radiologically labeled [18F]. Compound 58 presented high radiochemical purity (>98%), high in vitro biostability, and good tumor uptake values in S180-bearing mice, with a tumor/muscle ratio of 2.08 and a tumor/bone ratio of 2.48 at 30 min of injection.

Figure 18. Design and synthesis of F-18-labelled 2, 4-diaminopyrimidine-type FAK-targeted inhibitors as potential tumor-imaging agents.
3.3. FAK Inhibitors of Pyrimidine Heterocyclic Compounds

2,4-Diaminopyrimidine is the main scaffold of FAK inhibitors, which exhibited the inhibitory activity against FAK and cancer cells. Therefore, many groups adopted the scaffold hopping strategy, replacing the core pyrimidine scaffold with pyrimidine heterocyclics, such as 7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine scaffold and thieno[3,2-d]pyrimidine scaffold to design novel FAK inhibitors.

7H-pyrrolo[2,3-d]pyrimidine derivative 59 (Figure 20) is a novel FAK inhibitor reported by Cheng’s group in 2019 [103]. They focused on the replacement of the 2,4-diaminopyrimidine core with the pyrimidine heterocyclic scaffold. They assumed it is feasible to introduce additional interactions with Glu500 by simply adding a hydrogen donor in this region, which would lead to the hinge binding part containing three donor-acceptor interactions, while the pyrimidine contains two cases. Besides, they introduced various substituents of R1 with hydrogen bond acceptors to form hydrogen bond interactions with Asp564 of the DFG motif. The introduction of dimethyl phosphine oxide moiety at R1 was favorable to increase activity against FAK. In addition, they further explored SAR at R2 with the dimethyl phosphine oxide substituted phenyl group at R1 position. A further modification is to introduce a substituted benzene ring or a substituted pyrazole ring at R2 to improve the efficacy and adjust the properties, and finally, focus on the R3 position of the phenyl group in position R2 on the pyrimidine. Since the para-substitution...
carrier R₃ points to the solvent region, the introduction of hydrophilic fragments at the R₃ position can help improve activity. A class of fragment-containing derivatives with different hydrophilic properties were discovered, and most of these compounds showed strong inhibitory potency against FAK. They also designed and synthesized compounds 61, 62, 63, and 64 containing thieno[2,3-d]pyrimidine or thieno[3,2-d]pyrimidine scaffold based on representative compounds 59 and 60 as FAK inhibitors.

**Figure 20.** Compounds 59 and 61 replaces 2,4-diaminopyrimidine scaffolds by pyrrolo-pyrimidine 2,4-diamine and thieno-pyrimidine 2,4-diamine scaffolds.

Among them, compounds 59 and 60 exhibited great inhibitory potency of FAK with IC₅₀ values of 5.4 and 23.1 nM, respectively. Compared with compounds 59 and 60, the inhibitory activity of thieno-pyrimidine analogs 61, 62, 63, and 64 against FAK was reduced by more than five times. These results indicate that the hydrogen bond between 7H-pyrrolo[2,3-d]pyrimidine and Glu500 helps to obtain high efficiency. In addition, compound 59 displayed inhibition activity against A549 cells with an IC₅₀ value of 3.2 µM, and also induced A549 cells apoptosis and suppressed its migration in a dose-dependent manner. Moreover, compound 59 exhibited good metabolic stability in mouse, rat, and
human liver microsomes. The results of the docking study indicated compound 59 was anchored to the hinge region via the canonical donor-acceptor-donor hydrogen-bonding motif between the nitrogen molecules on the 7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine moiety and the backbone of residues Glu500 and Cys502 (Figure 21). The hydrophobic interaction by hydrophobic side chains of the Ala 452 and Leu 553 helps increase further stabilization. The dimethyl phosphine oxide moiety interacts with Asp564 of the DFG motif through hydrogen bonding.

Figure 21. (A) Chemical structure of compound 59. (B) Predicted binding mode of compound 59 in the ATP-binding site of FAK (PDB ID: 2JKK).

Thieno [3,2-d]pyrimidine derivative 67 is a potent FAK inhibitor reported by Cheng’s group in 2020 [104] (Figure 22). Based on a cyclization strategy, Cheng’s group used 2,7-disubstituted-thieno[3,2-d]pyrimidine scaffold to mimic the bioactive conformation of the well-known diaminopyrimidine scaffold of FAK inhibitors. First, they focused on the R₁ moiety by fixing the R₂ moiety as a phosphonate group. In R₁ moiety, different fragments containing hydrogen bond acceptors were introduced to form hydrogen bond interactions with Asp564 of the DFG motif. Compound 65 contains a 2-methoxy group at the R₁ position, which exhibited the strongest inhibitory potency on FAK (IC₅₀ = 134 nM). Then, Cheng’s group performed SAR detection at R₂. The introduction of the N-substituted formamide group (compound 66, IC₅₀ = 38.8 nM) produced twice the effectiveness of compound 65. Based on compound 66, the substituents of the benzene ring were changed to further explore the SAR. The introduction of F at 3-position of benzene ring maintained high efficacy against FAK (IC₅₀ = 28.8 nM). In addition, they also explored the influence of the changes on the solubilizing groups at the R₆ position. The optimized piperidine-4-yl-substituted compound 67 has a high inhibitory activity against FAK (IC₅₀ = 28.2 nM). Compound 67 also exhibited excellent antiproliferation activity against U-87MG, A549, and MDA-MB-231 cells (IC₅₀ = 0.16, 0.27, and 0.19 µM, respectively), which were significantly lower than that of the lead compound TAE-226 (IC₅₀ = 1.67, 1.16, and 4.06 µM, respectively). In addition, compound 67 could significantly induce cell apoptosis, arrest cell cycle at the G0/G1 phase, and suppress migration in MDA-MB-231 cells. The results of the docking study elucidate the possible binding modes of compound 67 and provide a structural basis for the further design of FAK inhibitors (Figure 23).
Gray’s group reported a new class of FAK inhibitors with a tricyclic benzopyrimidodiazepinone core in 2021 [105]. Previous studies suggested that the tricyclic benzopyrimidodiazepinone scaffold is a privileged scaffold for the design of kinase inhibitors, for example, BJG-01-181 (compound 72) was identified as a FAK inhibitor (IC$_{50}$ $= 62.2$ nM) in the biochemical kinase assay. Therefore, they explored the structure–activity relationships of this novel scaffold to improve the inhibitory potency of FAK (Figure 24). In addition, the N-methylated compounds usually have better pharmacokinetic (PK) properties than the secondary amides [106], so they designed N-methylated tricyclic benzopyrimidodiazepinone core to provide compounds including compounds 74, 75, and 76 with enhanced FAK inhibitory potency. Based on compound 73, they further explored SAR of the substituent group on benzopyrimidodiazepinone core including compounds 77 and 78.
Figure 23. The predicted docked pose of compound 67 (yellow sticks) in the FAK active site (PDB: 2JKK). Detailed interactions with the protein residues. Each dashed red line represents hydrogen bonds.

Figure 24. Discovery of a pyrimidothiazolodiazepinone as a potent and selective focal adhesion kinase (FAK) inhibitor.
Compound 73, an N-methyl matched-pair with compound 72, was synthesized and exhibited a three-fold improvement against FAK with an IC\textsubscript{50} value of 20.2 nM. A variety of modifications provided inhibitors 74, 75, and 76 with IC\textsubscript{50} values in the 30–60 nM range. N-ethylation at any position of the central ring retained nearly identical inhibitory potency of FAK as compound 73. In addition, compound 73 exhibited potent activity in 3D-culture breast and gastric cancer models, and favorable pharmacokinetic properties in mice. The results of the docking study suggested that compound 73 revealed two hydrogen-bonding interactions with FAK protein, which might explain the potent inhibitory of compound 73 (Figure 25).

3.4. FAK Inhibitors with a Triazine Scaffold

Triazine ring is often reported as an important scaffold for anticancer drugs [107,108]. For example, furazil and dioxadet, which contain different amino groups at positions 2, 4, or 6, have been reported as anticancer drugs. Because the chlorine atom of the triazine nucleus can easily be substituted successively with nucleophilic groups, resulting in a variety of substitutions, many groups develop new FAK inhibitors with a triazine scaffold.

Pyrrolo[2,1-f][1,2,4]triazine 82 is a potent inhibitor of dual FAK and JAK2 developed by Zifisak’s group in 2012 [109]. Pyrrolo[2,1-f][1,2,4]triazine usually was designed as a core scaffold of ALK inhibitors, and Zifisak’s group screened 79 showing potent inhibitory activity against JAK2 (IC\textsubscript{50} = 0.2 nM) and good potency of FAK (IC\textsubscript{50} = 17 nM). In addition, bioavailable ALK inhibitor 80 showed potent FAK activity but modest inhibition of JAK2. Therefore, Zifisak’s group designed a new class of pyrrolo[2,1-f][1,2,4]triazines as dual inhibitors of FAK and JAK2 based on the compounds 79 and 80 (Figure 26). Compound 81 showed strongest inhibitory effect on JAK (IC\textsubscript{50} = 2.0 nM) and FAK (IC\textsubscript{50} = 14 nM). Compound 81 was further optimized by introducing a chlorine atom into the pyrrolo [2,1-f][1,2,4]triazine ring to obtain compound 82. Progress has been made in FAK and JAK2 dual inhibitors, which showed potent inhibitory activity against both FAK and JAK2. In addition, compound 82 potently inhibited p-STAT3 and p-FAK phosphorylation in CWR22 tumor mice xenografts.
Figure 26. Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases.

Diarylamino-1,3,5-triazine derivative 87 was identified as a novel FAK inhibitor reported by Chen’s group in 2013 [110] (Figure 27). Chen’s group first introduced a 3,4,5-trimethoxyanilino group and a methanesulfonamide phenyl group on the 1,3,5-triazine ring to obtain compound 85 with poor activity against FAK (IC\(_{50}\) = 41.9 µM). Next, they removed the chlorine atom of the triazine ring based on compound 85 to give compound 86, which showed approximately eight-fold inhibitory activity against FAK (IC\(_{50}\) = 5.1 µM). Substituting an amide moiety (compound 87) for the complex sulfonamide group (compound 86) could significantly increase the inhibitory activity 13 times against FAK (IC\(_{50}\) = 0.4 µM). Chen’s group also explored the influence of the changes of the 3,4,5-trimethoxyanilino group on FAK activity (compounds 88, 89, 90, and 91).

Among of these compounds, compound 88 exhibited high inhibitory activity against both FAK (IC\(_{50}\) = 0.31 µM) and HUVEC cells growth (IC\(_{50}\) = 1.5 µM). In addition, the crystal structure of compound 88 in the FAK protein was resolved (PDB ID: 4brx), which indicated compound 88 interacting with the FAK kinase domain is highly similar to that of the lead compound TAE-226 (Figure 28).

Chen’s group reported novel imidazo[1,2-\(\alpha\)][1,3,5]triazines as FAK inhibitors in 2015 [111]. Based on the studies of triazine FAK inhibitor 87, they designed novel compounds by the fusing imidazole ring with the triazine to give an imidazo[1,2-\(\alpha\)][1,3,5]triazine (Figure 29). Imidazo[1,2-\(\alpha\)][1,3,5]triazine 92 exhibited stronger binding affinity to FAK (2-fold) than that of compound 87, showing specific contributions of imidazo[1,2-\(\alpha\)][1,3,5]triazine. SAR was further explored and Chen’s group designed compounds 94 and 95 with a CH\(_2\)NH\(_2\) group or CH\(_2\)NHAlloc group in the para position of the simple phenyl ring, which exhibited more potent inhibitory activity of FAK (IC\(_{50}\) = 120 and 50 nM, respectively) than that of compound 87.
Figure 27. Designs and synthesis of diarylamino 1,3,5-triazine derivatives as FAK inhibitors.

Figure 28. (A). Chemical structure of compound 88. (B). Compound 88 is shown to bound to the active site of the FAK kinase (beige ribbon with activation looping cyan, PDB ID: 4brx). Key side chains and the inhibitors (yellow) are shown in stick representation.
Figure 29. Designs and synthesis of imidazo[1,2-a][1,3,5]triazine cyclic FAK inhibitors. Compared to TAE-226, compound 95 significantly inhibited the autophosphorylation of FAK Y397 in HCT-116, MDA-MB-231, U-87MG, and PC-3 cells. In addition, compound 95 exhibited excellent antiproliferation activity against HCT-116, and PC-3 cells (IC\textsubscript{50} = 0.52, and 0.29 µM, respectively). Compound 95 also potently inhibited the cell-matrix adhesion, migration, and invasion of U87-MG cells in a dose-dependent manner. The results of the molecular docking studies suggested that compound 95 is very similar as observed for compound 87 (Figure 30). However, imidazo[1,2-a] ring could make additional interactions, most notably with Met499, CH\textsubscript{2}NH group forms a hydrogen bond interaction with Ile-428, and the CO of the alloc group in compound 95 also could produce an additional interaction with Glu506, which might explain the increased binding affinity of compound 95 to FAK.

Figure 30. Docking of compound 87 (A) and 95 (B) into the ATP-binding pocket of FAK (PDB ID: 4c7t).

Although the interaction mode of TAE-226 and compound 88 is very similar, compound 88 exhibited lower in vitro potency of FAK about 45 times than that of TAE-226. Chen’s group proposed that one major reason from X-ray structure is the missing chlorine atom in 1,3,5-triazine compounds, which in TAE-226 makes van der Waals interactions with Met499 of FAK kinase, therefore, Chen’s group developed 1,2,4-triazine compounds
as a novel scaffold for FAK inhibitors which can contain a chlorine atom at position 6 of 1,2,4-triazine core in 2017 (Figure 31) [112].

Among these compounds, compound 98 containing a \(2-\text{OCH}_3\)-4-morpholino group showed the best anti-FAK activity with an IC\(_{50}\) value of 230 nM and excellent antiproliferation activity against HCT-116 cells (IC\(_{50}\) = 0.19 \(\mu\)M). The results of the docking studies suggested that the van der Waals interactions between the chlorine atom and Met499 of FAK protein might not be important to the binding of compound 98 with FAK protein, suggesting that the weaker hydrogen bonds between the amino 1,2,4-triazine and the hinge region of FAK may play an important role in the inhibitory activity of compound 98 (Figure 32).

Among these compounds, compound 98 containing a \(2-\text{OCH}_3\)-4-morpholino group showed the best anti-FAK activity with an IC\(_{50}\) value of 230 nM and excellent antiproliferation activity against HCT-116 cells (IC\(_{50}\) = 0.19 \(\mu\)M). The results of the docking studies suggested that the van der Waals interactions between the chlorine atom and Met499 of FAK protein might not be important to the binding of compound 98 with FAK protein, suggesting that the weaker hydrogen bonds between the amino 1,2,4-triazine and the hinge region of FAK may play an important role in the inhibitory activity of compound 98 (Figure 32).

Figure 31. Design and synthesis of 1,2,4-triazine derivatives as FAK inhibitors.

Figure 32. (A) Chemical structure of compound 98. (B) compound 98 is shown bound to the active site of the FAK kinase (beige ribbon with activation looping cyan, PDB ID: 4brx). Key side chains and the inhibitors (yellow) are shown in stick representation.
3.5. Other Types of FAK Inhibitors

Many groups also reported five-membered heterocyclic compounds containing nitrogen as FAK inhibitor (Figure 33), including 1,3,4-thiadazole derivatives 102 and 103 [113,114], 1,3,4-oxadiazole derivatives 104 and 105 [115,116], 2-styryl-5-nitroimidazole derivatives 106 [117], 1,2,4-triazole derivative 107 [118]. Most of these compounds exhibited inhibitory activity and antiproliferative activity at the micromolar levels.

Zhu’s group reported a new class of novel 1,3,4-thiadazoles as FAK inhibitors. The most active compound 102 inhibited the activity of FAK and HepG2 cells with an EC_{50} value of 10.79 and 10.28 µM, respectively (Figure 33). Furthermore, Zhu’s group designed and synthesized 1,3,4-thiadazol-2-amide derivatives with more potent inhibitory potency of FAK and cancer cells growth compared to 102 [114]. The most active compound 103 exhibited better inhibitory activity against FAK with an IC_{50} value of 5.32 µM and inhibited proliferation of MCF-7 and B16-F10 cells with IC_{50} values of 0.45 and 0.31 µM, respectively [113]. The results of docking studies suggested that compounds 102 and 103 could be well embedded in the ATP-binding pocket of FAK through a hydrogen bond, π–σ interaction, and π–cation interaction (Figure 34).

Zhu’s group designed a new class of 1,3,4-oxadiazole-2(3H)-thiones as FAK inhibitors by replacing the 1,3,4-thiadiazole core of compounds 102 and 103 with further modifications. The most active compound 104 exhibited significantly the inhibitory activity of FAK (Phospho-Tyr397) with an IC_{50} value of 19.5 µM in C6 cells [116]. Compound 105 also showed potent anticancer activity against C6 cells (IC_{50} = 4.63 µM) and caused higher caspase-3 activation and morphological changes.

Figure 33. Nitrogen-containing 5-membered heterocyclic FAK inhibitors.
In 2014, Zhu’s group also designed novel 2-styryl-5-nitroimidazole derivatives as FAK inhibitors with antiproliferative activity [117]. Compound 106 exhibited potently inhibitory activity against FAK (IC$_{50}$ = 0.45 µM), and A549 and HeLa cells growth with IC$_{50}$ values of 0.45, 3.11 µM, respectively. In addition, compound 106 induced HeLa cells apoptosis in a dose-dependent manner. Compound 106 could decrease the phosphorylation of PI3K, Akt, JNK, and STAT3, resulting in apoptosis induction and cell cycle arrest. The results of molecular docking revealed that compound 106 could well fit within the ATP-binding site of FAK. In 2021, Hayallah’s group reported a new class of 1,2,4-triazole derivatives as FAK inhibitors with potential anticancer activity [118]. The most active compound 107 inhibited the activity of FAK with an IC$_{50}$ value of 18.10 nM and inhibited HepG2 and Hep3B cells growth with IC$_{50}$ values of 3.78 and 4.83 µM, respectively.

Miki’s group reported 1,5-dihydropyrazolo[4,3-c][1,2]benzothiazines as novel FAK inhibitors by high-throughput screening (HTS) (Figure 35). The HTS of the internal compound library of this research group gave more than ten hit compounds of different chemical classes, and further modification gives compounds 109 and 110. Compound 109 and 110 inhibited the FAK activity with IC$_{50}$ values 0.64 and 4.2 µM, respectively [119].

Figure 34. Molecular docking modeling of compound 102 (A) and compound 103 (B) with FAK.

Figure 35. Design and synthesis of an allosteric inhibitor 110 targeting FAK.
4. The Discovery of FAK-Targeting PROTACs and Their Therapeutic Significance

The proteolytic targeting chimera (PROTAC) is a new chemical knockout technique for post-translational proteins. PROTAC is a heterogeneous bifunctional small molecule containing two recognition parts: one specifically binds to E3 ubiquitin ligase, and the other specifically binds to the target protein. The PROTAC molecule can drive the E3 ubiquitin ligase to the target protein, which leads to the ubiquitination of the target protein, which leads to proteasome-mediated degradation (Figure 36) [120,121].

Figure 36. (A) FAK protein schematic. FAK-PROTACs can act on both enzymatic and nonenzymatic functions of FAK, while FAK inhibitor only acts on the enzymatic function of FAK. (B) Schematic depiction of the PROTAC strategy.

Crew’s group reported potent FAK selective degraders in 2018 [122]. In this work, they designed FAK degraders by conjugating a FAK ligand derived from VS-6063 (defactinib) through slight modifications with a peptide-based VHL ligand or thalidomide through ether linkers (Figure 37). All of these FAK PROTACs exhibited good inhibitory potency against FAK and could significantly induce the degradation of FAK at low concentrations. Among the FAK-PROTACs, compound 111 exhibited potent activity, which showed an \( \text{IC}_{50} \) value of 6.5 nM, DC\(_{50} \) value of 3 nM, and Dmax over 99%. Compound 111 displayed better selectivity to FAK than VS-6063. In addition, compound 111 displayed significant effects in suppressing the FAK downstream signaling pathways, which could highly induce the degradation of FAK in a dose-dependent manner with only 34% total FAK remaining at 10 nM and 5% at 50 nM, which outperformed VS-6063 (defactinib). In addition, compound 111 significantly reduces p-paxillin levels by as much as 85–90% at 50 nM, p-Akt suppression of 93% at 1 \( \mu \)M, and is more effective than VS-6063. Compound 111 also significantly inhibited the migration and invasion of MDA-MB-23 cells.

Ettmayer’s group reported a new class of FAK-PROTACs represented by compounds 113 and 114 in 2019, by tethering a previously identified FAK inhibitor compound 112 through an ether linker with a peptide-based VHL ligand and pomalidomide, respectively [123] (Figure 38). Both of FAK-PROTACs (compound 113 and 114) showed comparable degradation potencies and efficacies with mean pDC\(_{50} \) values of 7.45 and 7.08 nM, respectively. The CRBN-based PROTAC 113 potently degraded FAK (DC\(_{50} = 27 \)nM) with a Dmax of 95% at the chosen experimental conditions, while the VHL-based PROTAC 114 only achieved a Dmax of 80% and was less potent (DC\(_{50} = 243 \)nM) in the A549 cells. However, although the potent depletion of FAK, both FAK-PROTACs (compound 113 and 114) did not exhibit antiproliferation activity against the tested cell lines in either short or long-term assays,
which indicated that scaffolding function of FAK may not be required for the proliferation of the tested cell lines.

**Figure 37.** Bifunctional pyrimidine 111 as a proteolytic targeting chimera of focal adhesion kinase (FAK).

**Figure 38.** Compounds 113 and 114 as a proteolytic targeting chimera of FAK.
Rao’s group reported a new class of FAK-PROTACs in 2020, by tethering a previously identified FAK inhibitors VS-6062 or VS-6063 through different ether linker with a CRBN E3 ligand pomalidomide [124] (Figure 39). They noticed that shorter diethylene or triethylene glycol linkers exhibited higher degradation activity of FAK. Among them, compound 115 caused rapid and significant degradation of FAK with DC$_{50}$ values at the scale of picomolar in TM3, PA1, MDA-MB-436, LNCaP, and Ramos cells (DC$_{50}$ = 310, 80, 330, 370, and 40 pM, respectively). Compound 115 showed a significant inhibitory effect on the autophosphorylation of FAK (pFAK$_{tyr397}$) below 1 nM, but VS-6062 showed an inhibitory effect on pFAK$_{tyr397}$ only at 3µM. However, the efficient knockdown of FAK by compound 115 did not more severely affect the proliferation of the tested cell lines.

Figure 39. Compound 115 as a proteolytic targeting chimera of focal adhesion kinase.

Gray’s group reported a new class of FAK-PROTACs by tethering a previously identified FAK inhibitor VS-4718 through an ether linker with a CRBN E3 ligand pomalidomide in a 2018 patent. All of them could effectively produce degradation of FAK with a Dmax of 85–100% at 100 nM, and compound 120, 121, 122, and 123 only achieved it at 10 nM [125] (Figure 40).
Figure 40. The proteolytic targeting chimera of focal adhesion kinase.

5. Concluding Remarks and Prospects

FAK is an intracellular non-receptor tyrosine kinase that promotes tumor cell growth by controlling cell adhesion, migration, proliferation, and survival. Therefore, targeting FAK is considered to be a promising cancer therapy with small molecules.

At present, a variety of FAK inhibitors have been proven to exhibit good antitumor activity. A comprehensive analysis of the mode of action of various FAK inhibitors shows that most of the inhibitor cores are composed of five-membered or six-membered nitrogen-containing heterocycles, which can be selectively inserted into the ATP-binding pocket of FAK and interact with the kinase hinge. The nitrogen atoms on the heterocycle could form key hydrogen bonds with the amino acid residues of FAK, and the heterocycle itself can form hydrophobic interactions with the surrounding residues. At the same time, the interaction between the branch chain of the core and FAK can further enhance the activity of the inhibitor, and the modification of the branch chain can also improve the drug ability of the inhibitor. FAK inhibitors have special effects on the FAK protein through the active groups in the structure, inhibiting the phosphorylation of phosphorylation sites (such as Tyr 397, Tyr 576, and Tyr 577) in the FAK structure, and inhibiting the overexpression of FAK, thereby exerting antitumor effect. So far, there is no approved FAK inhibitor in the market. Therefore, there is an urgent need to develop new FAK inhibitors with higher antitumor activity to exert stronger antitumor effects. Combining more anticancer therapies to treat human cancer is a frequently used strategy. The joint research of FAK inhibitors and other anticancer drugs will also be in the direction of FAK inhibitor development. PROTAC technology has also been applied to the development of FAK drugs. Several potential FAK PROTACs have been reported, which opens a new window for FAK-targeted therapy.

Funding: This research received no external funding.

Acknowledgments: This work was supported by the National Natural Sciences Foundations of China (No. 81703541 & U2004123 for Sai-Yang Zhang and No. 81673322 for Yan-Bing Zhang) and China Postdoctoral Science Foundation (No. 2018M632812 for Sai-Yang Zhang). Henan Association of Science and Technology (No. 2020HYTP056 for Sai-Yang Zhang, China) and Science and Technology Department of Henan Province (No. 20202310144, for Sai-Yang Zhang, China). The open fund of state key laboratory of Pharmaceutical Biotechnology, Nan-jing University, China (Grant no. KF-GN-202104).

Conflicts of Interest: The authors declare no conflict of interest.
27. Jones, S.F.; Siu, L.L.; Bendell, J.C.; Cleary, J.M.; Razak, A.R.A.; Infante, J.R.; Pandya, S.S.; Bedard, P.L.; Pierce, K.J.; Houk, B.; et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. *Invest. New Drugs* **2015**, *33*, 1100–1107. [CrossRef] [PubMed]

28. Stokes, J.B.; Adair, S.J.; Slack-Davis, J.K.; Walters, D.M.; Tilghman, R.W.; Hershey, E.D.; Lowrey, B.; Thomas, K.S.; Bouton, A.H.; Hwang, R.F.; et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. *Cancer Ther.* **2011**, *10*, 2135–2145. [CrossRef]

29. Lu, Y.; Sun, H. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK). *J. Med. Chem.* **2020**, *63*, 14382–14403. [CrossRef]

30. Fu, Q.; Socki, R.A.; Niles, P.B. Evaluating reaction pathways of hydrothermal abiotic organic synthesis at elevated temperatures using carbon isopes. *Geochim. Cosmochim. Acta* **2015**, *154*, 1–17. [CrossRef]

31. Rosado, P.; Lequerica-Fernández, P.; Peña, I.; Alonso-Durán, L.; de Vicente, J.C. In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression. *Vircus Arch.* **2012**, *461*, 163–168. [CrossRef] [PubMed]

32. Zheng, Y.; Gierut, J.; Wang, Z.; Miao, J.; Asara, J.M.; Tyner, A.L. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. *Oncogene* **2013**, *32*, 4304–4312. [CrossRef] [PubMed]

33. Lim, S.-T.; Chen, X.L.; Lim, Y.; Hanson, D.A.; Vo, T.-T.; Howerton, K.; Larocque, N.; Fisher, S.J.; Slaplaef, D.D.; Ilic, D. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. *Mol. Cell* **2008**, *29*, 9–22. [CrossRef] [PubMed]

34. Hamadi, A.; Bouali, M.; Donentwill, M.; Stoeckel, H.; Takeda, K.; Rondé, P. Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397. *J. Cell Sci.* **2005**, *118*, 4415–4425. [CrossRef]

35. Scheswohl, D.M.; Harrell, J.R.; Rajfur, Z.; Gao, G.; Campbell, S.L.; Schaller, M.D. Multiple paxillin binding sites regulate FAK function. *J. Mol. Signal.* **2008**, *3*, 1. [CrossRef]

36. Lawson, C.; Lim, S.-T.; Uryu, S.; Chen, X.L.; Calderwood, D.A.; Slaplaef, D.D. FAK promotes recruitment of talin to nascent adhesions to control cell motility. *J. Cell Biol.* **2012**, *196*, 223–232. [CrossRef]

37. Subauste, M.C.; Pertz, O.; Adamson, E.D.; Turner, C.E.; Junger, S.; Hahn, K.M. Vinculin modulation of paxillin–FAK interactions regulates ERK to control survival and motility. *J. Cell Biol.* **2004**, *165*, 371–381. [CrossRef]

38. Cho, J.-H.; Muralidharan, V.; Vila-Perello, M.; Raleigh, D.P.; Muir, T.W.; Palmer, A.G. Tuning protein autoinhibition by domain destabilization. *Nat. Struct. Mol. Biol.* **2011**, *18*, 550–555. [CrossRef]

39. Golubovskaya, V.M.; Kwen, F.A.; Cance, W.G. Focal adhesion kinase and cancer. *Histol. Histopathol.* **2015**, *30*, 499–509. [CrossRef]

40. Zhang, J.; He, D.-H.; Zajac-Kaye, M.; Hochwald, S.N. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. *Cancer Ther.* **2011**, *10*, 2135–2145. [CrossRef]

41. Subauste, M.C.; Pertz, O.; Adamson, E.D.; Turner, C.E.; Junger, S.; Hahn, K.M. Vinculin modulation of paxillin–FAK interactions regulates ERK to control survival and motility. *J. Cell Biol.* **2004**, *165*, 371–381. [CrossRef]

42. Roberts, W.; Ung, E.; Whalen, P.; Cooper, B.; Hulford, C.; Autry, C.; Richter, D.; Emerson, E.; Lin, J.; Kath, J.; et al. Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271. *Cancer Res.* **2008**, *68*, 1935–1944. [CrossRef] [PubMed]

43. Crompton, B.D.; Carlton, A.L.; Thorner, A.R.; Christie, A.L.; Du, J.; Calicchio, M.L.; Rivera, M.N.; Fleming, M.D.; Kohl, N.E.; Kung, A.L.; et al. High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma. *Cancer Res.* **2013**, *73*, 2873–2883. [CrossRef]

44. Bagi, C.M.; Christensen, J.; Cohen, D.P.; Roberts, W.G.; Wilkie, D.; Swanson, T.; Tuthill, T.; Andresen, C.J. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a three-dimensional environment. *Cancer Biol. Ther.* **2009**, *8*, 856–865. [CrossRef] [PubMed]

45. Stone, R.L.; Baggerly, K.A.; Armaiz-Pena, G.N.; Kang, Y.; Sanguino, A.M.; Thanapatprasit, D.; Dalton, H.J.; Botsford-Miller, J.; Zand, B.; Akbani, R.; et al. Focal adhesion kinase. *Cancer Biol. Ther.* **2014**, *15*, 919–929. [CrossRef] [PubMed]

46. Infante, J.R.; Camidge, D.R.; Mileskin, L.R.; Chen, E.X.; Hicks, R.J.; Rischin, D.; Fingert, H.; Pierce, K.J.; Xu, H.; Roberts, W.G.; et al. Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors. *J. Clin. Oncol.* **2012**, *30*, 1527–1533. [CrossRef]

47. Tanjoni, I.; Walsh, C.; Uryu, S.; Tomar, A.; Nam, J.-O.; Mielgo, A.; Lim, S.-T.; Liang, C.; Koenig, M.; Patel, N.; et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. *Cancer Biol. Ther.* **2010**, *9*, 764–777. [CrossRef]

48. Kurmasheva, R.T.; Gorlick, R.; Kolb, E.A.; Keir, S.T.; Maris, J.M.; Lock, R.B.; Carol, H.; Kang, M.; Reynolds, C.P.; Wu, J.; et al. Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. *Pediatric Blood Cancer* **2017**, *64*, e26304. [CrossRef]

49. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP–dependent transporters. *Nat. Rev. Cancer* **2002**, *2*, 48–58. [CrossRef]

50. Eckford, P.D.W.; Sharam, F.J. ABC Efflux Pump-Based Resistance to Chemotherapy Drugs. *Chem. Rev.* **2009**, *109*, 2989–3011. [CrossRef]

51. Stavrovskaya, A.A.; Stromska, T.P. Transport proteins of the ABC family and multidrug resistance of tumor cells. *Biochemistry* **2008**, *73*, 592–604. [CrossRef] [PubMed]
74. Shanthi, E.; Krishna, M.H.; Arunesh, G.M.; Reddy, K.V.; Kumar, J.S.; Viswanadhan, V.N. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: A patent review. Expert Opin. Ther. Pat. 2014, 24, 1077–1100. [CrossRef]

75. Cao, F.Y.; Zhou, X.P.; Su, J.; Yang, X.H.; Mu, F.H.; Shen, J.Y.; Sun, W. Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors. Anti Cancer Agents Med. Chem. 2016, 16, 934–941. [CrossRef] [PubMed]

76. Sulzmaier, F.J.; Jean, C.; Schlaepfer, D.D. FAK in cancer: Mechanistic findings and clinical applications. Nat. Rev. Cancer 2014, 14, 988–910. [CrossRef]

77. Lee, M.Y.; Kim, M.H.; Kim, J.; Kim, S.H.; Kim, B.T.; Jeong, I.H.; Chang, S.; Kim, S.H.; Chang, S.-Y. Synthesis and SAR of sulfonyl- and phosphonyl amidine compounds as anti-resorptive agents. Bioorg. Med. Chem. Lett. 2010, 20, 541–545. [CrossRef]

78. Huttunen, K.M.; Rautio, J. Prodrugs—An efficient way to breach delivery and targeting barriers. Curr. Top. Med. Chem. 2011, 11, 2265–2287. [CrossRef]

79. Kamiyama, A.; Nakajima, M.; Han, L.; Wada, K.; Mizutani, M.; Tabuchi, Y.; Kojima-Yuasa, A.; Matsui-Yuasa, I.; Suzuki, H.; Fukuyama, K.; et al. Phosphonate-based irreversible inhibitors of human γ-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity. Bioorg. Med. Chem. 2016, 24, 5340–5352. [CrossRef]

80. Ge, Y.; Yang, H.; Wang, C.; Meng, Q.; Li, L.; Sun, H.; Zhen, Y.; Liu, K.; Li, Y.; Ma, X. Design and synthesis of phosphonyl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton’s tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. Bioorg. Med. Chem. 2017, 25, 765–772. [CrossRef] [PubMed]

81. Zhao, D.; Huang, S.; Qu, M.; Wang, C.; Liu, Z.; Li, Z.; Peng, J.; Liu, K.; Li, Y.; Ma, X.; et al. Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton’s tyrosine kinase (BTK) inhibitors with improved activity toward B cell leukemia cell lines. Eur. J. Med. Chem. 2012, 46, 444–455. [CrossRef] [PubMed]

82. Ge, Y.; Jin, Y.; Wang, C.; Zhang, J.; Tang, Z.; Peng, J.; Liu, K.; Li, Y.; Zhou, Y.; Ma, X. Discovery of Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold. ACS Med. Chem. Lett. 2016, 7, 1050–1055. [CrossRef]

83. Liu, H.-M.; Lee, C.-W. Reply to Letter to the Editor “Concern on article “Predicting procedure successful rate and 1-year patency after endovascular recanalization for chronic carotid artery occlusion by CT angiography””. Int. J. Cardiol. 2017, 229, 60. [CrossRef] [PubMed]

84. Liu, H.; Wu, B.; Ge, Y.; Huang, J.; Song, S.; Wang, C.; Yao, J.; Liu, K.; Li, Y.; Li, Y.; et al. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines. Bioorg. Med. Chem. 2017, 25, 6313–6321. [CrossRef] [PubMed]

85. Wu, F.; Xu, T.; He, G.; Ouyang, L.; Han, B.; Peng, C.; Song, X.; Xiang, M. Discovery of Novel Focal Adhesion Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approach Based on Multicomplex-Based Pharmacophore and Molecular Docking. Int. J. Mol. Sci. 2012, 13, 15668–15678. [CrossRef]

86. Wang, L.; Ai, M.; Yu, J.; Jin, L.; Wang, C.; Liu, Z.; Shu, X.; Tang, Z.; Liu, K.; Luo, H.; et al. Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cell lines. Eur. J. Med. Chem. 2019, 172, 154–162. [CrossRef]

87. Sanderson, K. Irreversible kinase inhibitors gain traction. Nat. Rev. Drug Discov. 2013, 12, 649–651. [CrossRef]

88. Singh, J.; Petter, R.C.; Baillie, T.A.; Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 2011, 10, 307–317. [CrossRef]

89. Barf, T.; Kaptein, A. Irreversible protein kinase inhibitors: Balancing the benefits and risks. J. Med. Chem. 2012, 55, 6243–6262. [CrossRef]

90. Yen-Pon, E.; Li, B.; Acebén-García-de-Eulate, M.; Tomkiewicz-Raulet, C.; Dawson, J.; Lietha, D.; Frame, M.C.; Coumoul, X.; Garbay, C.; Ethève-Quelquejue, M.; et al. Structure-Based Design, Synthesis, and Characterization of the First Irreversible Focal Adhesion Kinase Inhibitor. ACS Chem. Biol. 2013, 8, 2067–2073. [CrossRef]

91. Viegas-Junior, C.; Danuello, A.; Bolzan, D.; Barreiro, E.J.; Fraga, C.A.M. Molecular hybridization: A useful tool in the design of new drug prototypes. Curr. Med. Chem. 2007, 14, 1829–1852. [CrossRef]

92. Fu, D.-J.; Zhang, L.; Song, J.; Mao, R.-W.; Zhao, R.-H.; Liu, Y.-C.; Hou, Y.-H.; Li, J.-H.; Yang, J.-J.; Jin, C.-Y.; et al. Design and synthesis of formononetin-dithiocarbamate hybrids that inhibit growth and migration of PC-3 cells via MAPK/Wnt signaling pathways. Eur. J. Med. Chem. 2017, 127, 87–99. [CrossRef]

93. Fu, D.-J.; Zhang, S.-Y.; Liu, Y.-C.; Zhang, L.; Liu, J.-J.; Song, J.; Zhao, R.-H.; Li, F.; Sun, H.-H.; Liu, H.-M.; et al. Design, synthesis and antiproliferative activity studies of novel dithiocarbamate–chalcone derivates. Bioorg. Med. Chem. Lett. 2016, 26, 3918–3922. [CrossRef]

94. Su, Y.; Li, R.; Ning, X.; Lin, Z.; Zhao, X.; Zhou, J.; Liu, J.; Jin, Y. Yin, Y. Discovery of 2,4-diarylamino pyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities. Eur. J. Med. Chem. 2019, 177, 32–46. [CrossRef]

95. Ai, M.; Wang, C.; Tang, Z.; Liu, K.; Sun, X.; Ma, T.; Li, Y.; Ma, X.; Li, L.; Chen, L. Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines. Bioorg. Chem. 2020, 94, 103408. [CrossRef] [PubMed]

96. Fang, S.; Wang, Z. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des. Dev. Ther. 2014, 8, 1595–1611.
97. Jotte, R.M.; Spigel, D.R. Advances in molecular-based personalized non-small-cell lung cancer therapy: Targeting epidermal growth factor receptor and mechanisms of resistance. Cancer Med. 2015, 4, 1621–1632. [CrossRef] [PubMed]

98. Kobayashi, S.; Boggan, T.J.; Dayaram, T.; Jänne, P.A.; Kocher, O.; Meyerson, M.; Johnson, B.E.; Eck, M.J.; Tenen, D.G.; Halmos, B. EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. N. Engl. J. Med. 2005, 352, 786–792. [CrossRef]

99. Kwak, E.L.; Sordella, R.; Bell, D.W.; Godin-Heymann, N.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Driscoll, D.R.; Fidias, P.; Lynch, T.J.; et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 2005, 102, 7665–7670. [CrossRef] [PubMed]

100. Li, B.; Li, Y.; Tomkiewicz-Raulet, C.; Dao, P.; Lietha, D.; Yen-Pon, E.; Du, Z.; Coumoul, X.; Garbay, C.; Etcheve-Quelquejeu, M.; et al. Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma. J. Med. Chem. 2020, 63, 12707–12724. [CrossRef]

101. Qi, Y.; Li, Y.; Fang, Y.; Qiang, B.; Gao, H.; Wang, S.; Zhang, H. Design, synthesis, and biological evaluation of F-18-labelled 2,4-diaminopyrimidine-type FAK-targeted inhibitors as potential tumour imaging agents. Bioorg. Med. Chem. Lett. 2020, 30, 127452. [CrossRef]

102. Qi, Y.; Li, Y.; Fang, Y.; Gao, H.; Qiang, B.; Wang, S.; Zhang, H. Design, Synthesis, Biological Evaluation, and Molecular Docking of 2,4-Diaminopyrimidine Derivatives Targeting Focal Adhesion Kinase as Tumor Radiotracers. Mol. Pharm. 2021, 18, 1634–1642. [CrossRef]

103. Wang, R.; Chen, Y.; Zhao, X.; Yu, S.; Yang, B.; Wu, T.; Guo, J.; Hao, C.; Zhao, D.; Cheng, M. Design, synthesis and biological evaluation of novel 7H-pyrrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents. Eur. J. Med. Chem. 2019, 183, 111716. [CrossRef] [PubMed]

104. Wang, R.; Yu, S.; Zhao, X.; Chen, Y.; Yang, B.; Wu, T.; Hao, C.; Zhao, D.; Cheng, M. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors. Eur. J. Med. Chem. 2020, 188, 112024. [CrossRef] [PubMed]

105. Groendyke, B.J.; Nabet, B.; Mohardt, M.L.; Zhang, H.; Peng, K.; Koide, E.; Coffey, C.R.; Che, J.; Scott, D.A.; Bass, A.J.; et al. Discovery of a Pyrimidotiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor. ACS Med. Chem. Lett. 2021, 12, 30–38. [CrossRef]

106. Groendyke, B.J.; Powell, C.E.; Feru, F.; Gero, T.W.; Li, Z.; Szabo, H.; Pang, K.; Feutrill, J.; Chen, B.; Li, B.; et al. Benzopyrimidodi-azepinone inhibitors of TNK2. Bioorg. Med. Chem. Lett. 2020, 30, 126948. [CrossRef]

107. Song, J.; Cui, X.-X.; Wu, B.-W.; Li, D.; Wang, S.-H.; Shi, L.; Zhu, T.; Zhang, Y.-B.; Zhang, S.-Y. Discovery of 1,2,4-triazine-based derivatives as novel neddylation inhibitors and anticancer activity studies against gastric cancer MGC-803 cells. Bioorg. Med. Chem. Lett. 2020, 30, 126791. [CrossRef] [PubMed]

108. Fu, D.-J.; Song, J.; Hou, Y.-H.; Zhao, R.-H.; Li, J.-H.; Mao, R.-W.; Yang, J.-J.; Li, P.; Zi, X.-L.; Li, Z.-H.; et al. Discovery of 5,6-diaryl-1,2,4-triazines hybrids as potential apoptosis inducers. Eur. J. Med. Chem. 2017, 138, 1076–1088. [CrossRef]

109. Zi(rc)sac, C.A.; Gingrich, D.E.; Breslin, H.J.; Dunn, D.D.; Milkiewicz, K.L.; Theroff, J.P.; Thieu, T.V.; Underiner, T.L.; Weinberg, L.R.; Aimone, L.D.; et al. Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases. Bioorg. Med. Chem. Lett. 2012, 22, 133–137. [CrossRef]

110. Dao, P.; Jarray, R.; le Coq, J.; Lietha, D.; Loukaci, A.; Lepelletier, Y.; Hadi-Slimane, R.; Garbay, C.; Raynaud, F.; Chen, H. Synthesis of novel diarylaminol-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity. Bioorg. Med. Chem. Lett. 2013, 23, 4552–4556. [CrossRef]

111. Dao, P.; Smith, N.; Tomkiewicz-Raulet, C.; Yen-Pon, E.; Camacho-Artacho, M.; Lietha, D.; Herbeuval, J.P.; Coumoul, X.; Garbay, C.; Chen, H. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity. J. Med. Chem. 2015, 58, 237–251. [CrossRef] [PubMed]

112. Dao, P.; Lietha, D.; Etcheve-Quelquejeu, M.; Garbay, C.; Chen, H. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity. Bioorg. Med. Chem. Lett. 2017, 27, 1727–1730. [CrossRef]

113. Yang, X.-H.; Xiang, L.; Li, X.; Zhao, T.-T.; Zhang, H.; Zhou, W.-P.; Wang, X.-M.; Gong, H.-B.; Zhu, H.-L. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazole-2-amide derivatives as novel anticancer agents. Bioorg. Med. Chem. 2012, 20, 2789–2795. [CrossRef]

114. Sun, J.; Yang, Y.-S.; Li, W.; Zhang, Y.-B.; Wang, X.-L.; Tang, J.-F.; Zhu, H.-L. Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents. Bioorg. Med. Chem. Lett. 2011, 21, 6116–6121. [CrossRef] [PubMed]

115. Sun, J.; Ren, S.-Z.; Lu, X.-Y.; Li, J.-J.; Shen, F.-Q.; Xu, C.; Zhu, H.-L. Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazinone skeleton as potential FAK inhibitors. Bioorg. Med. Chem. 2017, 25, 2593–2600. [CrossRef] [PubMed]

116. Allntop, M.D.; Sever, B.; Çiftçi, G.A.; Turan-Zitouni, G.; Kaplanclı, Z.A.; Özdemir, A. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors. Eur. J. Med. Chem. 2018, 155, 905–924. [CrossRef]

117. Duan, Y.-T.; Yao, Y.-F.; Huang, W.; Makawana, J.A.; Teraiya, S.B.; Thuman, N.J.; Tang, D.-J.; Tao, X.-X.; Wang, Z.-C.; Jiang, A.-Q.; et al. Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity. Bioorg. Med. Chem. 2014, 22, 2947–2954. [CrossRef]
118. Mustafa, M.; Abuo-Rahma, G.E.-D.A.; El-Hafeez, A.A.A.; Ahmed, E.R.; Abdelhamid, D.; Ghosh, P.; Hayallah, A.M. Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton. *Bioorg. Med. Chem. Lett.* 2021, 40, 127965. [CrossRef]

119. Tomita, N.; Hayashi, Y.; Suzuki, S.; Oomori, Y.; Aramaki, Y.; Matsushita, Y.; Iwatani, M.; Iwata, H.; Okabe, A.; Awazu, Y.; et al. Structure-based discovery of cellular-active allosteric inhibitors of FAK. *Bioorg. Med. Chem. Lett.* 2013, 23, 1779–1785. [CrossRef] [PubMed]

120. Sun, Y.; Zhao, X.; Ding, N.; Gao, H.; Wu, Y.; Yang, Y.; Zhao, M.; Hwang, J.; Song, Y.; Liu, W.; et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. *Cell Res.* 2018, 28, 779–781. [CrossRef]

121. Raina, K.; Crews, C.M. Chemical Inducers of Targeted Protein Degradation*. *J. Biol. Chem.* 2010, 285, 11057–11060. [CrossRef] [PubMed]

122. Kargbo, R.B. Bifunctional Pyrimidines as Modulators of Focal Adhesion Kinase. *ACS Med. Chem. Lett.* 2020, 11, 409–411. [CrossRef] [PubMed]

123. Popow, J.; Arnhof, H.; Bader, G.; Berger, H.; Ciulli, A.; Covini, D.; Dank, C.; Gnaschitz, T.; Greb, P.; Karolyi-Özguer, J.; et al. Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions. *J. Med. Chem.* 2019, 62, 2508–2520. [CrossRef] [PubMed]

124. Gao, H.; Wu, Y.; Sun, Y.; Yang, Y.; Zhou, G.; Rao, Y. Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs. *ACS Med. Chem. Lett.* 2020, 11, 1855–1862. [CrossRef] [PubMed]

125. Kargbo, R.B. Chemically Induced Degradation of FAK-ALK for Application in Cancer Therapeutics. *ACS Med. Chem. Lett.* 2020, 11, 1367–1368. [CrossRef] [PubMed]